Carfilzomib,Lenalidomide
amgen
['bet', 'krd', 'gem-cesar', 'roche,(-broche),(-rocheter)']
dr. mateos presents at #ash22 gem-cesar study (including krd &amp; high-dose therapy) in high risk smoldering myeloma. 48 percent with biochemical progression at 70 m. mrd neg is obviously better. very few progressed to active mm. 
Hem/Onc, BMT, CAR-T, Immunology, Math, Machine Learning, Python, R, SAS. Tweets are my personal views